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LDL Receptor-Related Protein 5 (LRP5)
Affects Bone Accrual and Eye Development
in life when bone catabolism supersedes anabolism, the
significant loss of bone mass (osteoporosis) becomes
a common medical problem (Riggs and Melton, 1986).
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Summary In contrast to other heritable childhood disorders that
affect bone strength, patients with OPPG do not have
In humans, low peak bone mass is a significant risk identifiable defects in collagen synthesis, anabolic and
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the low-density lipoprotein receptor-related protein 5, dral growth, or bone turnover (Gong et al., 1996). Histo-
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in LRP5 cause the autosomal recessive disorder os- reveal deficient trabecular bone volume (Figures 1D and
teoporosis-pseudoglioma syndrome (OPPG). We find 1E) but normal surface density and appearance of osteo-
that OPPG carriers have reduced bone mass when blasts and osteoclasts on bone surfaces (data not
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Many patients with OPPG are born with severe disrup-thickness in mouse calvarial explant cultures. These
tion of ocular structure, phthisis bulbi. However, persis-data indicate that Wnt-mediated signaling via LRP5
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ing to speculation that ocular pathology results from
failed regression of the primary vitreal vasculature dur-
Introduction ing fetal growth.
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that obligate carriers of mutant LRP5 genes have re-
duced bone mass when compared to age- and gender-1 Correspondence: mlw14@po.cwru.edu
matched controls. We demonstrate that LRP5 is ex-2 These authors contributed equally to this work.
pressed by osteoblasts in situ and that its expression3 Authors’ affiliations are provided at http://www.cell.com/cgi/
content/full/107/4/513/DC1. pattern changes over time when pluripotent mesenchy-
Cell
514
Figure 1. Clinical Features of the Osteoporo-
sis-Pseudoglioma Syndrome
(A) Lower extremity photograph of a 40-year-
old female OPPG patient demonstrating an-
gular deformity of the tibia and fibula, the
consequence of multiple fractures occurring
during childhood.
(B) Lateral lumbar spine radiograph of a 10-
year-old male OPPG patient demonstrating
abnormal flattening and concavity of the lum-
bar vertebrae. Affected individuals have nor-
mal growth during the first few years of life,
but can fall below the normal range for height
because of long bone fractures and vertebral
collapse.
(C) Photograph of the right eye of a 3-month-
old male with OPPG demonstrating leukoco-
ria (a white mass behind the pupil resembling
retinoblastoma but actually a retrolental
membrane). This individual had persistence
of the tunica vasculosa partially covering the
anterior lens surface, and evaluation of the
dense retrolental membrane revealed a vas-
cular central stalk that extended from the optic nerve into the vitreous cavity.
(D and E) Iliac crest bone biopsies (both at 40 magnification) from an unaffected 2.5-year-old child (control) and from a 2.5-year-old child
with OPPG, respectively. The control biopsy is substantially thicker than the OPPG biopsy. Note that the bone volume in the control (D) allows
for only one cortical surface and a substantial trabecular bone network to be contained within the microscopic field. In contrast, both the
inner and outer cortices and very little trabecular bone are contained within the field of the OPPG patient (E).
mal cells are differentiated along the osteoblastic lin- cell lines were available from four unrelated families. We
employed RT-PCR to amplify and sequence the codingeage in vitro. We show that LRP5 is able to mediate Wnt
region of the LRP5 cDNA in the patients from thesesignaling in vitro via the canonical pathway and that
families, and we identified putative disease-causing mu-dominant-negative forms of LRP5 can interfere with this
tations in each sample (Figure 2A). We confirmed thatprocess. Lastly, we show that dominant-negative forms
the mutations were homozygous and inherited by usingof LRP5 can affect bone thickness in mouse calvarial
the patients’ and their parents’ genomic DNA. We thenexplant cultures. These data indicate that LRP5 affects
began performing an exon-by-exon search for disease-the accrual of bone mass during Wnt-mediated osteo-
causing mutations in the remaining families. To date,blastic proliferation and differentiation.
we have identified a total of six different homozygous
frameshift or nonsense mutations in affected offspring
Results from consanguineous families (Figure 2A). We have also
found homozygous missense mutations in affected pa-
Mutations in LRP5 Cause OPPG tients from two other consanguineous families and het-
Twenty-eight families affected by OPPG participated in erozygous nonsense, frameshift, and missense muta-
this study. The genetic mapping of OPPG has been tions in affected patients from four nonconsanguineous
described (Gong et al., 1996). We found that genomic families (Figure 2A). The nonconsanguineous patients
sequence from three overlapping 11q13 large insert clones likely have a second mutant allele that we have not yet
(GenBank accession numbers AC024126, AC024123, and detected since their parents (who are also heterozygous
AC024124) contained three simple sequence-repeat for the mutations) do not have OPPG. Neither these
polymorphisms (D11S1337, D11S4087, and D11S4178) mutations nor a shared haplotype were observed among
as well as exons coding for LRP5. Because one noncon- the remaining families, suggesting that there is not a
sanguineous OPPG family had a single affected child common ancestral mutation or a mutational hotspot.
who was homozygous for all three SSRP markers, we Putative disease-causing missense mutations have not
hypothesized that this individual is homozygous for an been found in control DNA samples; however, we have
ancestral haplotype that also contains an OPPG dis- not yet determined that they are disease causing by
ease-causing mutation. Therefore, we sequenced the means of a functional assay.
LRP5 gene. Two affected siblings are homozygous for a nonsense
LRP5 cDNA contains a 4.9 kb open reading frame codon within the signal peptide domain of LRP5. This
(Chen et al., 1999; Dong et al., 1998; Hey et al., 1998; would suggest that loss-of-LRP5 function is the mecha-
Kim et al., 1998). Comparison of the LRP5 cDNA with the nism of mutational effect in OPPG. Because other non-
genome sequences deposited in GenBank (see above) sense and frameshift mutations occurred within the re-
indicates that LRP5 comprises 23 coding exons that ceptor’s extracellular domain, it remains possible that
span 100 kb. Surprisingly, we also identified an unpro- OPPG could also result from a dominant-negative mech-
cessed pseudogene containing exons 3–9 on human chro- anism by allowing a ligand binding portion of the recep-
mosome 22 (GenBank accession number AL022324). Pa- tor to be secreted and act as a decoy. To test this latter
hypothesis, we transiently transfected COS-7 cells withtient-derived fibroblast or EBV-transformed lymphoblastic
LRP5 Affects Bone Accrual and Eye Development
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cates that mutations in LRP5 may also be able to cause
disease via a dominant-negative mechanism; however,
the phenotype caused by this type of mutation could
be distinct from that observed in OPPG.
OPPG Carriers Also Have Reduced Bone Mass
We measured lumbar spine areal bone mineral density
(aBMD) in 17 patients, 6 unaffected siblings, and 20
parents (Table 1). We considered all parents of OPPG
patients as well as all unaffected siblings who had one
copy of an OPPG mutant allele or haplotype to be obli-
gate carriers. When compared to age- and gender-
matched controls, all OPPG patients had extremely low
aBMD (p  0.0001). The average aBMD for the 23 obli-
gate carriers was also significantly below the control
mean (p  0.001). These results indicate that OPPG
disease-causing mutations in LRP5 can have dominant
effects as well as recessive effects.
Lrp5 Is Expressed by Osteoblasts
We performed in situ hybridization on skeletal elements
in developing mice to determine possible sites of action
of Lrp5 during bone formation. The lateral half of the
mouse clavicle ossifies by membranous ossification be-
Figure 2. OPPG Is Caused by Mutation in LRP5 ginning on embryonic day 14.0, while the medial half
(A) The predicted structure of wild-type LRP5 is depicted. LRP5 ossifies later by endochondral ossification (Huang et al.,
contains a 29 amino acid signal peptide (red rectangle), 20 YWTD 1997). As shown in Figure 3A, we first detect skeletal
spacer repeat domains (yellow circles) interspersed by four EGF-like expression of Lrp5 in the cells that are forming the lateral
domains (blue rectangles), three LDL receptor-like ligand binding
part of the clavicle. These cells express other markersdomains (red ovals), a transmembrane domain (yellow rectangle),
of skeletal differentiation, such as alkaline phosphataseand a 200 amino acid residue cytoplasmic domain (blue oval). Six
disease-causing, homozygous frameshift and nonsense mutations and Runx2 (data not shown), although they have not yet
and their predicted effects upon the polypeptide sequence are begun to make a detectable mineralized matrix. During
shown above the diagram. Putative disease-causing homozygous embryonic day 16.5 when the diaphyseal bone collar is
missense mutations are shown below the diagram, as are heterozy- forming around the humerus, Lrp5 expression is noted
gous mutations (in italics) found in affected individuals from noncon-
in osteoblasts along the endosteal surface and not insanguineous unions. Mutation nomenclature follows recent recom-
growth plate chondrocytes (Figure 3B). In addition tomendations (http://www.dmd.nl/mutnomen.html). The locations of
the two dominant-negative LRP5 constructs (LRP5TM and the detection of osteoblastic expression in appendicular
LRP5C) are underlined. bones, expression was also noted in osteoblasts that
(B) Cell lysates (C) and conditioned media (M) from transiently trans- line the developing calvaria (Figure 3C). Postnatally,
fected COS-7 cells were separated on a 4%–20% gradient SDS- Lrp5 expression was observed in trabecular and cortical
PAGE gel under reducing conditions and immunodetected with anti-
osteoblasts in the appendicular skeleton in a 4-week-FLAG antibody. Transfection constructs included wild-type LRP5
old mouse (data not shown).(Wild-type), a secreted form of LRP5 that lacks the transmembrane
and cytoplasmic domains (TM), and two OPPG mutants E1270fs
and Q853X. Wild-type contains the transmembrane domain and is
LRP5 Expression Increases during BMP2-Inducedfound in the cell lysate. TM, which lacks the transmembrane do-
Differentiation of the ST2 Pluripotentmain, is secreted and recoverable from the conditioned media. Nei-
Mesenchymal Cell Line alongther E1270fs nor Q853X, which also lack the transmembrane domain,
are recoverable from conditioned media, indicating that they are syn- the Osteoblastic Lineage
thesized but not secreted. These mutant proteins might not even be Pluripotent marrow stromal cell lines are capable of be-
synthesized in vivo due to nonsense-mediated mRNA decay. ing induced along an osteoblastic lineage by the addi-
tion of exogenous growth factors (Katagiri et al., 1994;
Yamaguchi et al., 1996). The addition of 300 ng/ml ofmammalian expression constructs containing either
wild-type LRP5 (wt) or the disease-causing alleles BMP2 to confluent ST2 cells results in the expression
of several genes that are associated with osteoblasticE1270fs and Q853X to see if the mutant polypeptides
were capable of being secreted. As shown in Figure 2B, differentiation (Figure 4) (Aubin, 1998). Lrp5 and Lrp6
have low levels of expression in untreated ST2 cells.these mutant proteins are synthesized but not secreted
by COS-7 cells, indicating that they are unlikely to act However, BMP2 addition causes a significant increase
in Lrp5 and Lrp6 expression by 48 hr. This increasedvia a dominant-negative mechanism. Given the similarity
in phenotype among patients with OPPG, we speculate expression persists after other markers of osteoblastic
differentiation (Alpl, Col1a1, and Bglap) have dimin-that OPPG disease-causing alleles are loss-of-function.
However, we were able to create an artificial LRP5 con- ished. It is interesting that the increased Lrp5 expression
occurs in cells that are beginning to express the morestruct that lacks the transmembrane domain (LRP5TM)
and could be secreted (Figures 2A and 2B). This indi- differentiated osteoblastic phenotype. Since cells are
Cell
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Table 1. Quantitative Lumbar Spine Areal Bone Mineral Density in OPPG Patients and First-Degree Relatives
Bone Mineral Density Z Score
Subjects Number Families Sex (M/F) Age Range (Years) Mean (SD) Median (Range)
OPPG patients 17 12 9/8 2–46 4.7 (0.9) 5.0 (3.1 to 6.1)
Obligate carriers parents 20 11 10/10 36–73 1.3 (1.4) 1.7 (2.7 to 3.3)
siblings 3 3 1/2 13–20 2.3 (0.3) 2.1 (2.1 to 2.6)
all 23 11 11/12 13–73 1.4 (1.4) 1.7 (2.7 to 3.3)
Noncarriers siblings 3 2 3/0 12–26 1.0 (1.2) 1.4 (1.9 to 0.3)
still proliferating when Lrp5 expression begins to in- binding to LRP5 and LRP6 (Bafico et al., 2001; Semenov
crease at 24 hr, we cannot rule out the possibility that et al., 2001). Because of the strong skeletal phenotype
Lrp5 has a role in regulating the proliferation of these associated with LRP5 mutations, we examined the ef-
pre- and early osteoblasts. However, the observation fects of Wnt and LRP5 in cells that can differentiate
that increased Lrp5 expression persists throughout the along the osteoblastic lineage in vitro. We performed
later stages of osteoblastic differentiation suggests a transient transfection experiments using different Wnts
role for the receptor during terminal differentiation. We and studied the induction in expression of the osteoblas-
do not yet know the significance of the observation that tic markers alkaline phosphatase (ALP), Bglap, and
Lrp6 expression in this in vitro system appears to mirror Runx2 in the pluripotent mesenchymal cells C3H10T1/
that of Lrp5. 2 and ST2. Wnt3a was able to induce ALP activity in
both cell lines (Figures 5A and 5B) without having a
significant effect on Bglap or Runx2 gene expressionLRP5 Is Involved in Wnt-Mediated Signaling in
(data not shown). This effect was inhibited by coexpres-Pluripotent Mesenchymal Cells that Can Be
sion with a dominant-negative form of Disheveled, aInduced along the Osteoblastic Lineage
downstream participant in the canonical Wnt signalingStudies in mouse, Drosophila, and Xenopus suggest
pathway (data not shown). Wnt1 and Wnt2, which alsothat LRP6 serves as a coreceptor with Frizzled family
signal via the canonical pathway, also increased ALPmembers during Wnt-mediated signaling (Pinson et al.,
activity (data not shown). However, Wnt5a and Wnt4,2000; Tamai et al., 2000; Wehrli et al., 2000). In the Xeno-
which neither elevate the level of cytosolic -cateninpus axis duplication assay, LRP5 is also capable of
nor activate LEF1-dependent transcriptional activitymediating Wnt signaling (Tamai et al., 2000). Further-
(Shimizu et al., 1997), did not increase ALP activity inmore, in mammalian cells, LRP5 is capable of function-
C3H10T1/2 and ST2 cells (Figures 5A and 5B; Wnt4 dataing as a Wnt coreceptor in the canonical signaling path-
not shown). Further support for the role of the canonicalway that employs -catenin as a downstream effector
Wnt signaling pathway in this process is the ability of a(Mao et al., 2001). It has also been shown that the Wnt
antagonist Dickkopf interferes with Wnt signaling by constitutive active mutant form of -catenin (-catenin*)
Figure 3. In Situ Hybridization Reveals Lrp5 Expression in Skeletal Elements of the Developing Mouse Embryo
The boxes in the upper panels correspond to the magnified areas in the lower panels. The size bars indicate 50 m.
(A) Lrp5 expression is noted in differentiating osteoblasts that contribute to the lateral membranous part of clavicle at embryonic day 13.5
(T, trachea; S, scapula). Note that the medial portion of the clavicle, which will ossify later by endochondral ossification, does not express
detectable levels of Lrp5, nor does the later-ossifying scapula.
(B) Osteoblasts lining the bony trabeculae of the humerus at embryonic day 16.5 and not in growth plate chondrocytes.
(C) Osteoblasts on both surfaces of the temporal bone at embryonic day 17.5 (B, brain).
LRP5 Affects Bone Accrual and Eye Development
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Figure 4. BMP2 Induces Changes in the Expression of Lrp5, Lrp6,
and Other Markers of Osteoblastic Differentiation in Cultured ST2
Cells
Total RNA (5 g) from untreated ST2 cells (0 hr time point) or from
cells exposed to 300 ng/ml BMP2 for 12, 24, 48, 72, 96, and 144
hr were Northern blotted. cDNA probes included Lrp5, its closest
mammalian paralog Lrp6, alkaline phosphatase (Alpl), the 	1 chain
of the type I collagen (Col1a1), osteocalcin (Bglap), and  actin
(Actb). An ethidium bromide-stained 18S ribosomal RNA band dem-
Figure 5. Wnt/-Catenin Induces Alkaline Phosphatase (ALP) Activ-onstrates equivalent loading across lanes. Low levels of Lrp5 and
ity in C3H10T1/2 and ST2 CellsLrp6 expression are detected in untreated ST2 cells; expression
levels increase over time, but are still low when compared to other (A) C3H10T1/2 and (B) ST2 cells were transiently transfected with
empty vector (pcDNA3.1), Wnt3a, or Wnt5a expression constructs.mRNA species depicted in this figure. For example, the Lrp5 and
Lrp6 panels represent exposure to a phosphorimager screen for 4 ALP activity was measured in cell lysates 72 hr after transfection,
normalized to protein content, and expressed as nmol pnpp/min/days, whereas the Col1a1 panel represents only a 0.5 hr exposure.
g of protein. Wnt 3a, but not Wnt 5a, increases ALP activity in both
cell lines.
(C) C3H10T1/2 cells were transiently transfected with empty vector,(Morin et al., 1997) to also induce ALP activity in
wild-type -catenin (-catenin), or a constitutive active form ofC3H10T1/2 and ST2 cells (Figure 5C).
-catenin (-catenin*) expression constructs. ALP activity was mea-Since LRP5 is expressed in pluripotent cells that can
sured in cell lysates 72 hr after transfection, normalized to proteinbe induced along the osteoblastic lineage, we assessed
content, and expressed as nmol pnpp/min/g of protein. The stable
the effect of overexpression of LRP5 on Wnt3a-medi- mutant form of -catenin is able to increase ALP activity. All experi-
ated induction of ALP activity. By using COS-7 cells, ments were performed in triplicate and repeated three times. Data

one SD from one representative experiment is presented.we first showed that LRP5 overexpression enhances
Wnt3a-mediated TCF-1 activation (Figure 6A); however,
by using C3H10T1/2 or ST2 cells, we could not show
an effect of LRP5 overexpression on Wnt3a induction two dominant-negative forms decreased ALP activity
induced by Wnt3a in both C3H10T1/2 and ST2 cellsof ALP (Figure 6B). This may be because the concentra-
tion of downstream effectors of LRP5-mediated signal- (Figure 6B), strongly suggesting that LRP5 modulates
the inducing effect of Wnt3a. We then tested if domi-ing in these cells is limiting. Therefore, we explored the
consequence of a loss-of-LRP5 function in these cells. nant-negative LRP5 constructs could affect the induc-
tion of ALP by stimuli other than Wnt. Interestingly,It has been reported that a secreted form of LRP5 can
bind Wnt and that an LRP5 mutant lacking the cyto- LRP5C and LRP5TM significantly inhibited the induc-
tion of ALP by BMP2 in ST2 (Figure 6C) and C3H101/2plasmic tail can function as a dominant negative (Mao
et al., 2001). We therefore made two different constructs cells (data not shown). Moreover, ST2 cells that were
stably expressing LRP5C (LRP5C-ST2) were less ablein which the cytoplasmic tail (LRP5C) or the transmem-
brane domain and cytoplasmic tail (LRP5TM) were de- to express ALP in response to either Wnt3a (Figure 6D)
or BMP2 (data not shown), compared to ST2 cells stablyleted. LRP5C and LRP5TM did not enhance Wnt3a-
induced TCF-1 activation in cotransfection experiments expressing wild-type LRP5 (LRP5-ST2). However, when
we overexpressed the constitutive active -catenin mu-conducted in COS-7 cells (Figure 6A). Importantly, these
Cell
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Figure 6. Dominant-Negative Forms of LRP5 Inhibit ALP Activity Induced by Wnt3a and BMP2
(A) COS-7 cells were transiently cotransfected with TCF-1, TOPflash, pTK-Renilla, and Wnt3a expression constructs. Where indicated, empty
vector, LRP5, LRP5C, or LRP5TM expression constructs were added to the cotransfection mix. Luciferase activity was determined in cell
lysates 24 hr after transfection and normalized to Renilla signal. Wild-type LRP5 increases Wnt3a-stimulated luciferase induction, whereas
the mutant forms of LRP5 do not.
(B) C3H10T1/2 and ST2 cells were transiently cotransfected with Wnt3a and LRP5, LRP5C, or LRP5TM expression constructs. ALP activity
was measured in cell lysates 72 hr after transfection and normalized to protein level. The dominant-negative forms of LRP5 reduce Wnt3a
stimulation of ALP activity in these cells.
(C) ST2 cells were transiently transfected with empty vector (pcDNA3), LRP5C, or LRP5TM expression constructs. Sixteen hours after
transfection, cells were left untreated (BMP2) or treated with BMP2 at 100 ng/ml (BMP2) and cultured for an additional 72 hr. ALP activity
was measured in cell lysates and normalized to protein level. The dominant-negative forms of LRP5 reduce BMP2 stimulation of ALP activity
in these cells.
(D) ST2 cell lines that are stably expressing LRP5C (LRP5C-ST2) or wild-type LRP5 (LRP5-ST2) were transiently transfected with Wnt3a
expression vector or empty vector. ALP activity was determined in cell lysates 72 hr after transfection and normalized to protein level. There
is less Wnt3a-induced ALP activity in cells stably expressing the dominant-negative form of LRP5.
(E) ST2 cell lines that are stably expressing LRP5C (LRP5C-ST2) or wild-type LRP5 (LRP5-ST2) were transiently cotransfected with Gal4-
Smad1 expression construct, Gal4/luciferase reporter construct, and pTK-Renilla. Sixteen hours after transfection, cells were either left
untreated (BMP2) or treated with BMP2 at 100 ng/ml (BMP2) for 24 hr. Luciferase activity was determined in cell lysates and normalized
to Renilla level. There is no difference in Smad1-stimulated luciferase activity in cells stably expressing either wild-type or dominant-negative
LRP5. All the aforementioned experiments were performed in triplicate and each was repeated three times. Data
 one SD from representative
experiments is presented.
tant, both LRP5C-ST2 and LRP5-ST2 cells were able Conditioned Media Containing the Dominant-
Negative Secreted Form of LRP5 Reducesto increase ALP activity, indicating that the -catenin
pathway is still functioning and that LRP5C inhibitory Bone Accrual in Calvarial Explant Cultures
While pluripotent mesenchymal cell lines can be in-activity is upstream in this pathway (Figure 6D). Finally,
when we measured Smad1 transcriptional activity by duced into the osteoblastic lineage, they may not reflect
endogenous osteoblastic proliferation and differentia-using a GalSmad1-based one-hybrid assay, we found
that LRP5C-ST2 cells and LRP5-ST2 cells responded tion. Consequently, we sought to determine whether the
secreted form of LRP5 (LRP5TM) could interfere withalmost identically to the stimulation of BMP2 (Figure
6E). Therefore, the inability of LRP5C-ST2 cells to re- bone accrual in calvarial explant cultures. In three inde-
pendent experiments, explants that were cultured in thespond to BMP2 is not due to an alteration in the BMP2
signaling pathway. Altogether our data suggest that the presence of conditioned media from cells expressing
LRP5TM consistently had thinner bone, as determinedintegrity of Wnt/LRP5 signaling is necessary for the in-
duction of alkaline phosphatase in these cells. by ALP staining and von Kossa staining, than did ex-
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Figure 7. A Secreted Mutant Form of LRP5
Reduces Bone Formation in Calvarial Explants
(Left) Calvarial explants were cultured for 5
days in conditioned medium derived from
LRP5-WT- or LRP5TM-transfected COS-7
cells. A semidarkfield photograph depicts a
typical calverium after 5 days in culture. The
parietal (p), frontal (f), and occipital (o) bones
are noted. Coronal sections of the explants
were obtained midway through the parietal
bones (level of section is depicted by black
line).
(Middle) Representative coronal sections
through the left parietal bone demonstrate
less von Kossa staining (thickness of black areas by arrows) in explants cultured in LRP5TM conditioned media versus LRP5-WT-conditioned
media.
(Right) Mean thickness (
 one SD) at two sites (P1 and P2) in five explants cultured in LRP5TM-conditioned media is reduced in comparison
to five explants cultured in LRP5-WT-conditioned media (p  0.01).
plants that were cultured in conditioned media from cells cated in the Wnt signaling cascade (Pinson et al., 2000;
Wehrli et al., 2000). Arrow transduces Wg signaling asexpressing wild-type LRP5 (Figure 7). Thus, LRP5TM
is able to inhibit bone growth, presumably by binding and a coreceptor with Frizzled and is upstream in the Wg-
signaling cascade from the cytoplasmic second mes-interfering with secreted growth factors such as Wnts.
sengers Dishevelled, Lef, and -catenin (Wehrli et al.,
2000). Mice homozygous for an insertion mutation atDiscussion
the Lrp6 locus have multiple developmental defects
(Pinson et al., 2000) and resemble mice with targetedBone Mass and Eye Development
Are Affected by LRP5 mutations of individual Wnt genes that signal via the
canonical pathway (Uusitalo et al., 1999).We have shown that mutations in LRP5 affect bone
mass in humans. The recessive effect includes a severe We used pluripotent mesenchymal cells that could
be induced into the osteoblastic lineage by exogenousreduction in bone mass and ocular pathology, the osteo-
porosis-pseudoglioma syndrome (Figure 1), while the growth factors (Figure 4) to show that the Wnt/-catenin
signaling pathway can act upon these cells in a Smad-dominant effect appears to be reduced bone mass in
obligate carriers (Table 1). The mechanism of mutational independent manner (Figure 5). We further showed that
LRP5 is involved in this pathway, since reducing LRP5effect of the OPPG disease-causing mutations is likely
to be loss-of-function (Figure 2). Several independent function with either a transmembrane-anchored domi-
nant-negative receptor or a secreted decoy receptorobservations suggest that LRP5 regulates osteoblastic
proliferation or differentiation. First, the phenotype man- interfered with Wnt-induced ALP stimulation (Figure 6).
Therefore, our data support other functional studies thatifests during growth when osteoblastic anabolic activity
supersedes osteoclastic catabolic activity. Second, put LRP5 in the Wnt signaling cascade (Mao et al., 2001;
Tamai et al., 2000), and we extend these results by plac-Lrp5 is expressed by developing and mature osteo-
blasts in situ (Figure 3). Third, Lrp5 expression levels ing LRP5 and Wnt signaling in the cell differentiation
pathway and tissue affected by LRP5 loss-of-functionchange as cells differentiate along the osteoblastic lin-
eage in vitro (Figure 4). Dong et al. (1998) observed that mutations.
We also observed a dosage effect for LRP5 functionLRP5 expression levels differed in three osteoblast-like
tumor cell lines. The authors speculated that these dif- since heterozygous carriers of OPPG mutations can
have reduced bone mass. Dosage effects are not uniqueferences might reflect each tumor cell line being arrested
at a different stage of osteoblastic differentiation, al- to LRP5. Individuals who are heterozygous for LDL re-
ceptor loss-of-function mutations have the autosomalthough epigenetic changes altering gene expression in
these cells could not be excluded. Our data supports dominant phenotype familial hypercholesterolemia
(Brown and Goldstein, 1986). Also, Pinson et al. (2000)modulation of LRP5 expression during osteoblastic dif-
ferentiation. It is of interest that a Mendelian genetic observed a worsening of the vestigial tail phenotype (a
hypomorphic Wnt3a allele) when it was moved onto ahigh-bone-mass phenotype and a bone mass quantita-
tive trait locus have also been mapped to genetic inter- heterozygous Lrp6 loss-of-function background.
The Wnt family member(s) involved in LRP5-mediatedvals that contain LRP5 (Johnson et al., 1997; Koller et
al., 1998). Since reduced LRP5 expression appears to signaling during bone growth remain to be elucidated.
By using TCF activation in COS cells and ALP activitynegatively regulate bone mass, it is intriguing to specu-
late that other mutations or common polymorphisms, in osteoblastic cells, we could demonstrate a functional
interaction between LRP5 and Wnt family members thatwhich affect the expression or activity of LRP5, will posi-
tively regulate bone mass. signal via the canonical pathway, such as Wnt3a and
Wnt1, but not between LRP5 and Wnt family members
that utilize other signaling pathways, such as Wnt5a. ItLRP5 and Its Closely Related Superfamily
Members Are Involved in Wnt Signal Transduction is satisfying that Alpl is a downstream target of LRP5
signaling, since naturally occurring ALPL deficiency inLRP5 has two closely related paralogs, LRP6 in mam-
mals and Arrow in Drosophila, which have been impli- humans and induced Alpl deficiency in mice also leads
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to osteopenia and fractures (Fedde et al., 1999; Mornet, cient mice (Kim et al., 1998). Therefore, other LDL recep-
tor family members may provide functional redundancy2000; Wennberg et al., 2000). Several other genes with
roles in bone biology have also been reported as targets for LRP5 at other sites with respect to ligand binding and
internalization. Since the sole postnatal consequence ofof Wnt/-catenin signaling (Ai et al., 2000; Globus et al.,
1998; Gradl et al., 1999; Haertel-Wiesmann et al., 2000; LRP5 deficiency in humans is reduced bone accrual, it
is exciting to speculate that the pharmacological modu-Horiuchi et al., 1999; Jochum et al., 2000; Mann et al.,
1999; Moursi et al., 1996). Therefore, deficiency of LRP5 lation of LRP5 signaling in healthy individuals could posi-
tively affect peak bone mass and thereby reduce themay affect the expression of a series of genes that are
important during bone formation. risk for developing clinically significant osteoporosis in
later life.LRP5 is also important during eye development. The
OPPG phenotype in humans suggests that there is a
defect in the involution of the primary vitreal vasculature Experimental Procedures
that normally begins during the 13th gestational week
Clinical Assessment, Genotyping, and Mutational Analysis(Ko et al., 1985; Zhu et al., 2000); failure of this process
The study had the approval of the Institutional Review Board atleads to fibrosis and contracture. We suspect that the
University Hospitals of Cleveland. The diagnosis of OPPG was based
transient expression of LRP5 by cells within the vitreal upon the cooccurrence of congenital- or juvenile-onset eye disease
vasculature, or perhaps by other vitreous constituents, and low bone mass. Other genetic and environmental causes of
visual loss and low bone mass were excluded based on carefulis responsible for this involution process. In the mouse,
physical examination and laboratory testing. DNA from peripheralwhere regression of the primary vitreal vasculature oc-
blood and total RNA from cultured patient skin fibroblasts or EBV-curs postnatally (Ito and Yoshioka, 1999), we were un-
transformed lymphoblasts were extracted following standard meth-able to detect LRP5 expression in E17.5 vitreal vessels.
ods. A percutaneous iliac crest bone biopsy was performed and
LRP5 may have very low levels of expression in these analyzed with standard methods (Glorieux et al., 2000; Parfitt et al.,
vessels, may have transient expression that is too brief 1987) and compared to age-matched controls (Glorieux et al., 2000).
Polymorphic genetic markers were tested with established methodsto reliably observe, or may be expressed in low-abun-
(Gong et al., 1996). Primer pairs were designed to PCR amplify LRP5dance cells, such as vitreal macrophages. An essential
cDNA and all 23 coding exons from genomic DNA (primer sequencesrole for vitreal macrophages in triggering vitreal vessel
and conditions are available from the authors). PCR amplificationregression has been described (Lang and Bishop, 1993).
was performed with standard methods and amplimers were se-
Two other Mendelian genetic ocular disorders, auto- quenced directly. All identified mutations were confirmed at the
somal dominant familial exudative vitreoretinopathy genomic DNA level and were heterozygous in the patients’ parents.
In families with identified disease-causing mutations, an unaffected(FEVR) and autosomal dominant neovascular inflamma-
sibling’s carrier status was determined by mutation detection. Intory retinopathy (VRNI), also map to an interval con-
other families, a sibling’s carrier status was determined by linkage.taining LRP5 (Li et al., 1992; Stone et al., 1992). Visual
Putative disease-causing missense mutations were not found inloss is a common feature in both syndromes, although
50 control DNA alleles; however, control DNA was not matched
there is variable expression and obligate carriers can for ancestry.
be asymptomatic. Eye abnormalities have not been de-
scribed in parents of patients affected with OPPG, al- Quantitative Lumbar Spine Areal Bone Mineral
though they have not been systematically sought. The Density Measurement
Areal bone mineral density (g/cm2) of the lumbar spine (AP projec-pathogenesis of visual loss in OPPG appears distinct
tion) was measured by dual-energy X-ray absorptiometry (DEXA).from that observed in FEVR and VRNI; however, LRP5
Participants were studied in different countries using different DEXAexpression has also been detected in retinal tissue (Fi-
systems. Therefore, for statistical analyses each measure was con-gueroa et al., 2000), and therefore it is reasonable to
verted to a standard deviation score (z score) relative to appropriate
speculate that LRP5 mutations could cause FEVR or age- and gender-matched controls for the system that was used.
VRNI via different mechanisms of mutational effect. Statistically significant differences between the study groups’ mean
z scores and control means (z 0) were determined using Student’s
t test.LRP5 Loss-of-Function Mutations Cause
a Restricted Phenotype Despite
In Situ HybridizationBroad Expression
C57BL/6 wild-type mouse embryos were fixed in 4% paraformalde-LRP5 is expressed in several tissues, as determined by
hyde in 0.1 M phosphate buffer (PB) (pH 7.4) at 4C overnight. After
Northern blot analysis (Dong et al., 1998; Hey et al., immersion in 20% sucrose in PB, tissues were embedded in OCT
1998; Kim et al., 1998), immunohistochemistry (Figueroa compound, and frozen tissue sections were cut at a thickness of 8
m. Limbs from a 1-month-old mouse were fixed in 4% paraformal-et al., 2000), and in situ hybridization (Figueroa et al.,
dehyde for 5 days and decalcified in 0.5 M EDTA (pH 7.4) for 152000). Therefore, it is surprising that the phenotypic con-
days. After dehydration, tissues were embedded in paraffin andsequences of mutation are restricted to the skeleton
sections were cut at a thickness of 5 m. Tissues were deparaffin-and the eye. As suggested by Pinson et al. (2000), it is
ized and dehydrated before the in situ procedure.
possible that LRP6, which is also broadly expressed, Lrp5-specific antisense probes were synthesized to cover 700
has functional redundancy with LRP5 in many tissues. base pairs of cDNA upstream of the unique EcoRI site. Digoxigenin-
11-UTP-labeled single-strand ribo-probes were prepared with theIt is reasonable to consider that LRP5 may also bind and
DIG RNA-labeling kit (Roche) by in vitro transcription according tointernalize multiple ligands in a non-signal-transducing
the manufacturer’s protocol.capacity, similar to many other LDL receptor family
Hybridization was carried out as described (Bohme et al., 1995).members (Gliemann, 1998; Hussain et al., 1999). Evi-
Hybridization was detected using 4-nitroblue tetrazolium, 5-bromo-
dence to support this conjecture is that LRP5 can bind 4-chloro-3-indyl-phosphate (X-phosphate), and nitroblue tetrazo-
ApoE-enriched low-density lipoproteins and that LRP5 lium salt (NBT) as substrates for alkaline phosphatase at 4C for 8 hr.
After counter staining with 0.2% methyl-green, slides were allowed toexpression increases in the livers of LDL receptor-defi-
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dry and mounted with Glycergel (DACO). The specimens were ob- Gal4/luciferase reporter were constructed as described (Spinella-
Jaegle et al., 2001).served and recorded by a SPOT camera (Diagnostic Instruments).
BMP2 Induction of ST2 Cell Osteoblastic Differentiation Wnt and LRP5 Responsiveness Using C3H10T1/2, ST2,
The murine bone marrow stromal cell line ST2 was cultured in RPMI and COS-7 Cell Lines
1640 (Cellgro) supplemented with 10% FBS, 50 U/ml penicillin, and C3H10T1/2, ST2, and COS-7 cell lines were cultured (37C, 5% CO2),
50 g/ml streptomycin (GIBCO-BRL). Cells were plated at a density respectively, in 	-MEM, RPMI, and DMEM medium supplemented
of 2  104/cm2 in 25 cm2 flasks, and when confluent, osteoblastic with 10% heat-inactivated FBS. ST-2 stable cell lines were main-
differentiation was induced by the addition of recombinant human tained in the corresponding culture medium and supplemented with
BMP2 (Aventis) at 300 ng/ml. Cell cultures were then continued for G418 (500 g/ml). For treatment or transient transfection, cells were
up to 144 hr. Total RNA from cells was harvested at 0, 0.5, 1, 2, 3, plated at 2  104/cm2, and 24 hr later treatment or transfections
4, and 6 days following BMP2 addition by the use of the Trizol were carried out as indicated below.
reagent (GIBCO-BRL), following the manufacturer’s protocol. Cells plated in 24 well plates were transiently transfected with the
indicated construct (1 g) using Fugene 6 (Roche). For luciferase
reporter assays, 20 ng of pRL-TK (Promega), which encodes a Re-Northern Blot Analysis
nilla luciferase gene downstream of a minimal HSV-TK promoter,Total RNA isolated from cultured cells was separated in 1% agarose-
was systematically added to the transfection mix to assess transfec-formaldehyde gels (5 g total RNA/ lane) and transferred to
tion efficiency. When required, controls utilized the correspondingHybond-N membrane (Amersham Pharmacia) via standard meth-
empty vectors. Sixteen hours after transfection, cells were washed,ods. We made replicate Northern blots to minimize potential differ-
cultured in media containing 2% FBS, and either left unstimulatedences in observed mRNA expression associated with repeat hybrid-
or stimulated with BMP2 (100 ng/ml) for an additional 48 hr. Lucifer-ization. Equal loading across gels and transfer to membrane was
ase or ALP activity was determined in cell lysates.determined by ethidium bromide staining. Hybridization was per-
When luciferase reporter constructs were used, luciferase assaysformed overnight by Ultrahyb (Ambion), following the manufacturer’s
were performed with the Dual Luciferase Assay Kit (Promega) ac-protocol. cDNA probes were random prime labeled by standard
cording to the manufacturer’s instructions. Cell lysate (10 l) wasmethods. Analyzed mouse probes included Lrp5 nt 4101–5092 (Gen-
assayed first for firefly luciferase and then for Renilla luciferaseBank accession #NM_008513), Lrp6 nt 2918–3769 (GenBank acces-
activity. Firefly luciferase activity was normalized to Renilla lucifer-sion #NM_008514), Alpl, Bglap, Col1a1 (Sabatakos et al., 2000), and
ase activity.Actb.
ALP activity was determined in cell lysates by the Alkaline Phos-
phatase Opt kit (Roche Molecular Biochemicals). Cell lysates wereLRP5 Expression Constructs and Stable LRP5-Expressing
analyzed for protein content by using the micro-BCA Assay kitCell Lines
(Pierce), and ALP activity was normalized for total protein concen-LRP5 expression constructs were made with the pcDNA3 expres-
tration.sion vector (Invitrogen). Full-length cDNA was amplified by RT-PCR
Each experiment was performed in triplicate and was repeatedfrom human fibroblasts and subcloned. A FLAG antibody epitope
three times.was inserted into the wild-type construct after nucleotide 165 (the
insertion site is relative to the “A” in the ATG translation start site)
Isolation and Culture of Mouse Calvarial Explantsusing QUIKChange (Stratagene). QUIKChange was also used to
Calvaria were obtained from 1-day-old Swiss Webster outbred micecreate expression constructs containing the E1270fs and Q853X
(Taconic Farms). Skin and brain were dissected away. Whole cal-disease-causing mutations. Endogenous Pml I and Apa I restriction
varia were placed upside down in organ culture dishes (Falcon 3037)sites were used to generate the LRP5C and LRP5TM dominant-
on a bed of 1.0% Seakem GTG agarose gel (FMC). A shallow depres-negative receptors, respectively. All constructs were confirmed by
sion conforming to the shape of the calvarial explant had been madesequencing. Stable ST2 cell lines expressing either wild-type or an
before the agarose solidified by placing a glass bead on the agaroseLRP5C construct, generated by an endogenous BsrG I restriction
surface. The calvaria explants were then covered by a thin layer ofenzyme site, were generated following G418 selection.
1% agarose. The agarose was dissolved in 	-MEM (GIBCO-BRL)
containing 10% FBS, 100 g/ml ascorbic acid (Sigma), 5.0 mMGeneration of Wnt- and LRP5-Conditioned Media
-glycero-phosphate (Sigma), 50 U/ml penicillin, and 50g/ml strep-The Wnt3a-expressing cell lines have been described (Shibamoto
tomycin. The explants were incubated with 2 ml of conditionedet al., 1998; Tamai et al., 2000). Cells were maintained in DMEM
medium containing 100 g/ml ascorbic acid and 5.0 mM -glycero-containing 10% FBS. Wnt3a (10 ml) containing culture media were
phosphate. Medium was changed on days 1 and 3. The samplescollected every 2 days from 100 mm diameter culture dishes after
were harvested at day 5, fixed with 4% PFA, and embedded inthe cells became confluent.
OCT compound. Serial coronal sections, including bilateral parietalLRP5-conditioned media was generated by transiently transfect-
bones, were cut at 7 m thickness. ALP staining and von Kossaing 80% confluent COS-7 cells in 100 mm diameter dishes with 5
staining were performed, and pictures were taken with a SPOTg expression plasmid DNA using Fugene 6 (Roche) following the
camera. Thickness of the parietal bone at 1.2 mm (P1) and 2.4 mmmanufacturer’s protocol. Conditioned medium (10 ml) was collected
(P2) from the midline was measured on ALP-stained sections.at 24 and 48 hr after the cells recovered from the transfection. The
presence of the protein in conditioned media or cell extract was
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